Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice

  • Miller R
  • Harrison D
  • Astle C
 et al. 
  • 219

    Readers

    Mendeley users who have this article in their library.
  • 444

    Citations

    Citations of this article.

Abstract

Rapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival was extended by an average of 10% in males and 18% in females. Rapamycin attenuated age-associated decline in spontaneous activity in males but not in females. Causes of death were similar in control and rapamycin-treated mice. Resveratrol (at 300 and 1200 ppm food) and simvastatin (12 and 120 ppm) did not have significant effects on survival in male or female mice. Further evaluation of rapamycin's effects on mice is likely to help delineate the role of the mammalian target of rapamycin complexes in the regulation of aging rate and age-dependent diseases and may help to guide a search for drugs that retard some or all of the diseases of aging.

Author-supplied keywords

  • Life span
  • Rapamycin
  • Resveratrol
  • TOR

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Richard A. Miller

  • David E. Harrison

  • C. M. Astle

  • Joseph A. Baur

  • Angela Rodriguez Boyd

  • Rafael De Cabo

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free